Abstract
As first shown by Russell et al1,2, disodium ethane-1-hydroxy-1, 1 diphosphonate (E.H.D.P.) has a powerful depressive effect on the increased bone turnover which characterizes Paget’s disease of bone. When ingested in doses of greater than 5 mg per kg per day, however, it causes a mineralization defect in addition to having a marked antiosteoclastic effect1–6. Accordingly, a diphosphonate free of such a side-effect would be preferable for the treatment of not only Paget’s disease, but of any other condition of hyperosteoclastosis, whatever the mechanisms of osteoclastic differenciation. To date, two compounds have been suggested in this connection: 3 amino-1-hydroxy-propane-1, 1 diphosphonate (A.H.P.D.P.) investigated by Bijvoet and al.7, and disodium dichloromethylene diphosphonate (Cl2M.D.P.), a drug similar in structure to E.H.D.P.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
